 Ashley Frazer-Abel
Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 14 | 2022 | 281 | 4.040 |
Why?
| | Complement Activation | 11 | 2022 | 337 | 1.150 |
Why?
| | Laboratories | 2 | 2021 | 95 | 0.870 |
Why?
| | Immunoassay | 2 | 2021 | 95 | 0.780 |
Why?
| | Clinical Laboratory Techniques | 2 | 2018 | 86 | 0.670 |
Why?
| | Laboratories, Hospital | 1 | 2018 | 14 | 0.620 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 90 | 0.590 |
Why?
| | RNA, Transfer | 2 | 2008 | 118 | 0.510 |
Why?
| | Angioedemas, Hereditary | 2 | 2014 | 4 | 0.500 |
Why?
| | Macular Degeneration | 3 | 2022 | 152 | 0.470 |
Why?
| | RNA | 3 | 2008 | 807 | 0.460 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 660 | 0.450 |
Why?
| | Autoimmune Diseases | 4 | 2022 | 381 | 0.440 |
Why?
| | Complement Factor B | 4 | 2022 | 100 | 0.420 |
Why?
| | Anticodon | 2 | 2004 | 22 | 0.400 |
Why?
| | Angioedema | 1 | 2011 | 16 | 0.380 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2021 | 90 | 0.370 |
Why?
| | Nucleic Acid Conformation | 3 | 2008 | 670 | 0.370 |
Why?
| | Emergency Responders | 2 | 2021 | 33 | 0.360 |
Why?
| | T-Lymphocytes | 3 | 2009 | 1735 | 0.340 |
Why?
| | Immunologic Tests | 2 | 2021 | 16 | 0.330 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 149 | 0.330 |
Why?
| | Autoantibodies | 3 | 2021 | 1347 | 0.330 |
Why?
| | Specimen Handling | 2 | 2022 | 153 | 0.320 |
Why?
| | Cyclin-Dependent Kinase 4 | 2 | 2006 | 33 | 0.320 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2019 | 122 | 0.310 |
Why?
| | Humans | 44 | 2023 | 114043 | 0.300 |
Why?
| | Arthritis, Rheumatoid | 3 | 2021 | 1002 | 0.290 |
Why?
| | Kidney Diseases | 2 | 2021 | 349 | 0.290 |
Why?
| | Smoking | 3 | 2019 | 1382 | 0.280 |
Why?
| | Tars | 1 | 2006 | 4 | 0.270 |
Why?
| | Complement Factor H | 2 | 2019 | 60 | 0.260 |
Why?
| | Nicotine | 2 | 2009 | 265 | 0.260 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 37 | 0.260 |
Why?
| | Cell Cycle | 2 | 2006 | 541 | 0.240 |
Why?
| | Complement C3a | 3 | 2019 | 33 | 0.240 |
Why?
| | RNA, Transfer, Ser | 2 | 2008 | 4 | 0.240 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2023 | 18 | 0.220 |
Why?
| | Quality Control | 2 | 2021 | 143 | 0.220 |
Why?
| | Disease Susceptibility | 4 | 2020 | 316 | 0.210 |
Why?
| | Vitreous Body | 2 | 2022 | 101 | 0.210 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 25 | 0.210 |
Why?
| | Trichloroethylene | 1 | 2022 | 7 | 0.200 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 115 | 0.200 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 15 | 0.200 |
Why?
| | Protein Aggregates | 2 | 2019 | 65 | 0.200 |
Why?
| | Nuclear Proteins | 2 | 2004 | 591 | 0.200 |
Why?
| | Complement Inactivator Proteins | 1 | 2021 | 40 | 0.190 |
Why?
| | Extracellular Traps | 1 | 2021 | 40 | 0.190 |
Why?
| | Cross Reactions | 1 | 2021 | 118 | 0.190 |
Why?
| | Europe | 2 | 2020 | 332 | 0.180 |
Why?
| | Immunologic Factors | 2 | 2022 | 217 | 0.180 |
Why?
| | Reference Standards | 1 | 2021 | 159 | 0.180 |
Why?
| | Retinal Drusen | 1 | 2021 | 25 | 0.180 |
Why?
| | Magnesium | 3 | 2008 | 144 | 0.170 |
Why?
| | Sputum | 1 | 2021 | 286 | 0.170 |
Why?
| | Polyvinyl Chloride | 1 | 2019 | 5 | 0.160 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 317 | 0.160 |
Why?
| | Diethylhexyl Phthalate | 1 | 2019 | 9 | 0.160 |
Why?
| | Biological Products | 1 | 2022 | 166 | 0.160 |
Why?
| | Occupational Exposure | 1 | 2022 | 255 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 33 | 0.160 |
Why?
| | Complement C3 | 2 | 2019 | 188 | 0.160 |
Why?
| | Wet Macular Degeneration | 1 | 2019 | 32 | 0.160 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 44 | 0.160 |
Why?
| | Geographic Atrophy | 1 | 2019 | 49 | 0.160 |
Why?
| | Rheumatoid Factor | 1 | 2019 | 157 | 0.160 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 72 | 0.150 |
Why?
| | Mass Spectrometry | 1 | 2021 | 622 | 0.150 |
Why?
| | DNA-Binding Proteins | 2 | 2004 | 1311 | 0.150 |
Why?
| | Transcription Factors | 3 | 2004 | 1525 | 0.140 |
Why?
| | Complement Inactivating Agents | 1 | 2017 | 40 | 0.140 |
Why?
| | Inflammation | 4 | 2021 | 2464 | 0.140 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 49 | 0.140 |
Why?
| | Complement C3 Nephritic Factor | 1 | 2016 | 1 | 0.130 |
Why?
| | Critical Illness | 1 | 2021 | 640 | 0.130 |
Why?
| | Complement C5 | 1 | 2016 | 73 | 0.130 |
Why?
| | Riboflavin | 1 | 2016 | 7 | 0.130 |
Why?
| | Virus Inactivation | 1 | 2016 | 8 | 0.130 |
Why?
| | Animals | 10 | 2022 | 31565 | 0.130 |
Why?
| | Ebolavirus | 1 | 2016 | 34 | 0.130 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2016 | 33 | 0.130 |
Why?
| | Blood | 1 | 2016 | 94 | 0.130 |
Why?
| | Nanoparticles | 1 | 2019 | 312 | 0.130 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2015 | 29 | 0.120 |
Why?
| | RNA, Fungal | 3 | 2008 | 66 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 637 | 0.120 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2014 | 7 | 0.120 |
Why?
| | Autoimmunity | 1 | 2020 | 812 | 0.120 |
Why?
| | Disinfection | 1 | 2016 | 107 | 0.120 |
Why?
| | RNA, Transfer, Phe | 2 | 2008 | 9 | 0.120 |
Why?
| | Oligoribonucleotides | 1 | 2014 | 52 | 0.120 |
Why?
| | Oligonucleotides, Antisense | 1 | 2014 | 100 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 898 | 0.110 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 315 | 0.110 |
Why?
| | Antibodies, Viral | 3 | 2022 | 520 | 0.110 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 363 | 0.110 |
Why?
| | Comprehension | 1 | 2014 | 151 | 0.100 |
Why?
| | Base Sequence | 2 | 2008 | 2114 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2012 | 25 | 0.100 |
Why?
| | Birefringence | 2 | 2004 | 6 | 0.100 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2011 | 6 | 0.100 |
Why?
| | Cattle | 2 | 2008 | 918 | 0.100 |
Why?
| | Complement C4 | 1 | 2011 | 24 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 1880 | 0.100 |
Why?
| | Female | 15 | 2022 | 59325 | 0.090 |
Why?
| | Male | 14 | 2022 | 55396 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2020 | 3003 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 137 | 0.090 |
Why?
| | Mutation | 2 | 2020 | 3338 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2014 | 2783 | 0.080 |
Why?
| | Oligonucleotides | 2 | 2014 | 137 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 475 | 0.080 |
Why?
| | Complement C5a | 2 | 2019 | 59 | 0.080 |
Why?
| | Drug Packaging | 2 | 2019 | 42 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 2784 | 0.080 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 100 | 0.080 |
Why?
| | Particle Size | 2 | 2019 | 317 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2008 | 166 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 328 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2004 | 607 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2006 | 3861 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3254 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2022 | 766 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1331 | 0.070 |
Why?
| | Middle Aged | 8 | 2021 | 26605 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2012 | 1036 | 0.070 |
Why?
| | Cell Survival | 1 | 2009 | 1014 | 0.070 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2006 | 15 | 0.070 |
Why?
| | Enzyme Induction | 1 | 2006 | 83 | 0.070 |
Why?
| | G1 Phase | 1 | 2006 | 68 | 0.060 |
Why?
| | Aged | 6 | 2021 | 18969 | 0.060 |
Why?
| | Temperature | 1 | 2008 | 564 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 82 | 0.060 |
Why?
| | Macaca fascicularis | 2 | 2016 | 50 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 3397 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 787 | 0.060 |
Why?
| | Hemangiosarcoma | 1 | 2004 | 18 | 0.060 |
Why?
| | Adult | 7 | 2021 | 30375 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 78 | 0.060 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2004 | 82 | 0.060 |
Why?
| | Dog Diseases | 1 | 2004 | 41 | 0.060 |
Why?
| | Plasmids | 1 | 2004 | 343 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2004 | 111 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 88 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | United States | 1 | 2018 | 12137 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 280 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 31 | 0.050 |
Why?
| | Antibodies, Antinuclear | 1 | 2022 | 58 | 0.050 |
Why?
| | Cytokines | 2 | 2012 | 1824 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 89 | 0.050 |
Why?
| | Colorado | 2 | 2021 | 4090 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 143 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 101 | 0.050 |
Why?
| | Pancreas | 1 | 2023 | 276 | 0.050 |
Why?
| | Microspheres | 1 | 2021 | 123 | 0.050 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 92 | 0.050 |
Why?
| | Apoptosis | 1 | 2009 | 2349 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 496 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 245 | 0.040 |
Why?
| | Vitrectomy | 1 | 2020 | 57 | 0.040 |
Why?
| | Complement C4a | 1 | 2019 | 6 | 0.040 |
Why?
| | Plasticizers | 1 | 2019 | 12 | 0.040 |
Why?
| | Freezing | 1 | 2019 | 84 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2371 | 0.040 |
Why?
| | Syringes | 1 | 2019 | 41 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 89 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 51 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 121 | 0.040 |
Why?
| | South Carolina | 1 | 2019 | 40 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2004 | 2550 | 0.040 |
Why?
| | Cations, Divalent | 1 | 1999 | 51 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2173 | 0.040 |
Why?
| | Body Mass Index | 2 | 2019 | 1957 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 104 | 0.040 |
Why?
| | Drug Stability | 1 | 2019 | 151 | 0.040 |
Why?
| | Rheology | 1 | 2019 | 86 | 0.040 |
Why?
| | Yeasts | 1 | 1999 | 49 | 0.040 |
Why?
| | Protein Stability | 1 | 2019 | 156 | 0.040 |
Why?
| | Calcium | 1 | 2004 | 1089 | 0.040 |
Why?
| | HIV Infections | 1 | 2012 | 2453 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 130 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 98 | 0.040 |
Why?
| | Risk Factors | 2 | 2021 | 8614 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6306 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 385 | 0.040 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 39 | 0.040 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 12 | 0.040 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 18 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2019 | 445 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 445 | 0.040 |
Why?
| | Prolactin | 1 | 1997 | 96 | 0.040 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 82 | 0.040 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 24 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 614 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 381 | 0.040 |
Why?
| | Mice | 2 | 2022 | 14841 | 0.040 |
Why?
| | Adolescent | 4 | 2016 | 17800 | 0.040 |
Why?
| | Epitopes | 1 | 2019 | 434 | 0.040 |
Why?
| | Motivation | 1 | 2021 | 488 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 556 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 951 | 0.030 |
Why?
| | Complement Pathway, Alternative | 1 | 2017 | 113 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 162 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 655 | 0.030 |
Why?
| | Vero Cells | 1 | 2016 | 63 | 0.030 |
Why?
| | Complement C5b | 1 | 2015 | 4 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2384 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2020 | 666 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2017 | 220 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 347 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1182 | 0.030 |
Why?
| | Child | 3 | 2021 | 18400 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2014 | 1981 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 1997 | 283 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 308 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 1829 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 268 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1417 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1997 | 333 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2080 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 1997 | 1131 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1468 | 0.030 |
Why?
| | CD4-CD8 Ratio | 1 | 2012 | 19 | 0.030 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 12 | 0.030 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 19 | 0.030 |
Why?
| | Raltegravir Potassium | 1 | 2012 | 16 | 0.030 |
Why?
| | Funnel Chest | 1 | 2012 | 22 | 0.030 |
Why?
| | Chemokine CCL5 | 1 | 2012 | 43 | 0.030 |
Why?
| | Adipokines | 1 | 2012 | 42 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1381 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4402 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 2885 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4392 | 0.020 |
Why?
| | Signal Transduction | 2 | 2009 | 4501 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 405 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 256 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6195 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2012 | 313 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1656 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1836 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 178 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 2009 | 4 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2009 | 128 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6077 | 0.020 |
Why?
| | Young Adult | 2 | 2014 | 10444 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1469 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 545 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1997 | 2321 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1360 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 686 | 0.020 |
Why?
| | Receptors, Nicotinic | 1 | 2009 | 273 | 0.020 |
Why?
| | HIV-1 | 1 | 2012 | 768 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 959 | 0.020 |
Why?
| | Ploidies | 1 | 2004 | 17 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 155 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 331 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 426 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12521 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 754 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 440 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 9114 | 0.010 |
Why?
| | Cell Movement | 1 | 2004 | 863 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1997 | 24 | 0.010 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.010 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 1997 | 18 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 43 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 830 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 51 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 2698 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 170 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1611 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1997 | 49 | 0.010 |
Why?
| | Coenzymes | 1 | 1997 | 16 | 0.010 |
Why?
| | Catalysis | 1 | 1997 | 289 | 0.010 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 1997 | 59 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 228 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1997 | 119 | 0.010 |
Why?
| | Mediator Complex | 1 | 1997 | 52 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 845 | 0.010 |
Why?
| | Transfection | 1 | 1997 | 863 | 0.010 |
Why?
| | Binding Sites | 1 | 1997 | 1166 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1997 | 393 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 463 | 0.010 |
Why?
| | Protein Binding | 1 | 1997 | 1888 | 0.010 |
Why?
| | Rats | 1 | 1997 | 4913 | 0.010 |
Why?
|
|
Frazer-Abel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|